Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers

Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers

Objective We describe a phase II clinical trial of the combination of ribociclib and letrozole for treatment of relapsed oestrogen receptor (ER)-positive ovarian cancer (OC) and endometrial cancer (EC). The primary endpoint was the proportion of patients alive, progression-free survival (PFS), and s...

Full description

Bibliographic Details
Main Authors: Gretchen E Glaser, Gerardo Colon-Otero, Valentina Zanfagnin, Xiaonan Hou, Nathan R Foster, Erik J Asmus, Andrea Wahner Hendrickson, Aminah Jatoi, Matthew S Block, Carrie L Langstraat, Tri A Dinh, Matthew W Robertson, John K Camoriano, Kristina A Butler, John A Copland, S John Weroha
Format: Article
Language:English
Published: Elsevier 2020-10-01
Series:ESMO Open
Online Access:https://esmoopen.bmj.com/content/5/5/e000926.full

Internet

https://esmoopen.bmj.com/content/5/5/e000926.full

Similar Items